Regal Rexnord reports Q2 results on July 31 with a striking divergence between what analysts are saying and what insiders have been doing.
The Street has turned more constructive in recent weeks. Deutsche Bank initiated coverage with a Buy and a $286 target on July 20, while Citigroup raised its target to $260 from $240 just days earlier on July 14. Those moves push the consensus mean target to $260, implying roughly 23% upside from the current price of $210.87. The bullish thesis centres on Regal Rexnord's industrial automation and motion control franchise, where the company has delivered strong operational execution. Forward earnings momentum ranks in the 83rd percentile of the ORTEX universe on a 12-month forward year-on-year basis, underscoring why analysts see room to run.
Insiders tell a different story. In May, CEO Louis Pinkham sold shares across multiple transactions totalling roughly $3.3 million in aggregate proceeds. CFO Robert Rehard sold a further $1.3 million worth on May 22. A divisional president sold nearly $2 million on May 14. Net insider sales over the 90 days to early June exceeded $12 million — a meaningful signal that those closest to the business were trimming into the spring rally. These were not small disposals; they came when the stock was trading at or above current levels, between $200 and $216 per share.
Short sellers, by contrast, have been retreating. Short interest dropped 8.5% in a single session on July 24 and has fallen around 15% over the past month, bringing it to roughly 4.3% of the free float. Borrow conditions are extremely loose — availability runs at over 12 times the current short interest — so there is no squeeze pressure in the lending market. Options positioning is slightly more cautious than usual, with the put/call ratio at 0.78, modestly above its 20-day average of 0.72, but the z-score of just 0.81 does not suggest anything close to alarm. The stock slipped 4% over the past month but recovered 2.6% on the week heading into the print.
The July 31 print will therefore test whether the company can validate the Street's revived optimism with a revenue and margin delivery that justifies analyst targets sitting 23% above the current price — while giving investors a reason to look past the sustained insider selling that accompanied the stock's spring strength.
See the live data behind this article on ORTEX.
Open RRX on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
